TRiCares GmbH
tricares.com
Actively hiring
Cardiovascular Devices
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$124.5M
5 rounds on record
Latest round
$50M
Series D · Jul 2024 · 2 yr ago
Team
11-50
employees, estimated range
Grants
$2.7M
1 grant · CORDIS
Backers
1
Karista
The money's age
Long since its last round
26 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 24
Took on debt financing $21.6M · Pulse 2.0
Jul 27, 2024
Raised a round Series D $50M · Pulse 2.0
Sep 15, 2022
Raised a round Series C $50.8M · YahooFinance
Dec 1, 2018
Won a grant $2.7M · CORDIS
Jun 4, 2018
Raised a round Series B $23.8M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Jan 2026 | $21.6M | — | Pulse 2.0 |
| Series D | Jul 2024 | $50M | — | Pulse 2.0 |
| Series C | Sep 2022 | $50.8M | — | YahooFinance |
| Grant | Dec 2018 | $2.7M | — | CORDIS |
| Series B | Jun 2018 | $23.8M | — | wsj.com |
Registers and programsofficial lists and records that name the company
| Legal entity | TRiCares GmbH | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Karista Investors in similar startupsfunds that back the companies most like this one
backs Avive Solutions
backs HVR Cardio
Similar startupsby what they do, their industry and backers
HVR Cardio is a cardiovascular device company developing breakthrough solutions for mitral valve repair based on its proprietary HELIX…
Redefining mitral valve repair with CARLEN — a single-leaflet solution expanding options for TEER-eligible and previously untreatable…
AccuVein develops simple solutions to improve vascular access outcomes for patients undergoing IV therapy, venous access procedures, or…
Striving For Healthier Hearts. Mitral and Tricuspid valve regurgitation are a serious medical condition in which the valves leak blood…
Developing the next generation of left-heart access technologies.
Innovating Valve Repair. Versa Vascular is leading development of a novel tricuspid valve repair solution in Santa Cruz, California.
News
TRiCares Announces Initiation of TRICURE US IDE Pivotal Study for Topaz Tricuspid Valve Replacement System
Initiation of the TRICURE US IDE pivotal study represents the first of next-generation TTVR devices to enroll patients in the USMinneapolis, MN, USA and Paris, France and Munich, Germany, 9 July 2026 - TRiCares SAS (
Read more
Report
TRiCares: Up To €20 Million EIB Loan Secured To Advance Topaz Tricuspid Valve Replacement Trials
TRiCares SAS, a privately held medtech company developing a minimally invasive treatment for tricuspid regurgitation, said it has signed a loan agreement for up to €20 million in non-dilutive financing with the European Investment Bank, the long-term lend
Read more
Report
Report
TRiCares SAS: TRiCares Announces First Topaz Implantation in EU Pivotal Study
TRiCares Announces First Topaz Implantation in EU Pivotal Study Paris, France and Munich, Germany, September 24, 2024 - TRiCares SAS ("TRiCares"), a company pioneering a minimally-invasive
Read more
Report
TRiCares: Medical Device Company Raises $50 Million In Series D
TRiCares SAS, a privately held pioneer in the minimally invasive treatment of tricuspid regurgitation, announced it has raised $50 million (€46 million) in a Series D funding round. The funding round was raised from a single strategic investor.
Read more
Report
TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation
TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich, Germany, December 6, 2022 - TRiCares SAS (
Read more
Report
TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation
TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich, Germany, September 15, 2022 - TRiCares SAS (
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Aschheim
Germany
Registered seat
10-50 est. staff